BLINDED INDEPENDENT CENTRAL RESPONSE ASSESSMENT USING RECIST, MRECIST, AND CHOI CRITERIA IN PATIENTS TREATED WITH SORAFENIB FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

(1) Beaujon Hospital



This item was part of the Liver I session at UEG Week Stockholm 2011

This item can be cited as: Gut 2011; 60 (Suppl 3) A141